EA201000562A1 - Производные n-(пиразол-3-ил)бензамида в качестве активаторов глюкокиназы - Google Patents

Производные n-(пиразол-3-ил)бензамида в качестве активаторов глюкокиназы

Info

Publication number
EA201000562A1
EA201000562A1 EA201000562A EA201000562A EA201000562A1 EA 201000562 A1 EA201000562 A1 EA 201000562A1 EA 201000562 A EA201000562 A EA 201000562A EA 201000562 A EA201000562 A EA 201000562A EA 201000562 A1 EA201000562 A1 EA 201000562A1
Authority
EA
Eurasian Patent Office
Prior art keywords
activators
glukokinazes
pyrazol
benzamide
derivatives
Prior art date
Application number
EA201000562A
Other languages
English (en)
Other versions
EA017114B1 (ru
Inventor
Ларс Торе Бургдорф
Денис Карниато
Ульрих Эмде
Норберт Байер
Иоганнес Глайтц
Кристин Шарон
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201000562A1 publication Critical patent/EA201000562A1/ru
Publication of EA017114B1 publication Critical patent/EA017114B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)

Abstract

Новые гетероциклические соединения формулы Iв которой R, R, R, R, R, R, R, Alk и D имеют значения, указанные в п.1, являются активаторами глюкокиназы и могут применяться для предотвращения и/или лечения диабетов 1 и 2 типа, ожирения, невропатии и/или нефропатии.
EA201000562A 2007-10-09 2008-09-09 Производные n-(пиразол-3-ил)бензамида в качестве активаторов глюкокиназы EA017114B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07019692 2007-10-09
PCT/EP2008/007365 WO2009046802A1 (en) 2007-10-09 2008-09-09 N- ( pyrazole- 3 -yl) -benzamide derivatives as glucokinase activators

Publications (2)

Publication Number Publication Date
EA201000562A1 true EA201000562A1 (ru) 2010-10-29
EA017114B1 EA017114B1 (ru) 2012-09-28

Family

ID=39930500

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000562A EA017114B1 (ru) 2007-10-09 2008-09-09 Производные n-(пиразол-3-ил)бензамида в качестве активаторов глюкокиназы

Country Status (23)

Country Link
US (1) US8236824B2 (ru)
EP (1) EP2197849B1 (ru)
JP (1) JP5457358B2 (ru)
KR (1) KR20100066580A (ru)
CN (1) CN101821240A (ru)
AR (1) AR068749A1 (ru)
AU (1) AU2008310115B2 (ru)
BR (1) BRPI0818348A2 (ru)
CA (1) CA2701839A1 (ru)
CY (1) CY1113944T1 (ru)
DK (1) DK2197849T3 (ru)
EA (1) EA017114B1 (ru)
EC (1) ECSP10010163A (ru)
ES (1) ES2403105T3 (ru)
HR (1) HRP20130377T1 (ru)
IL (1) IL204750A0 (ru)
MX (1) MX2010003760A (ru)
NZ (1) NZ585237A (ru)
PL (1) PL2197849T3 (ru)
PT (1) PT2197849E (ru)
SI (1) SI2197849T1 (ru)
UA (1) UA99837C2 (ru)
WO (1) WO2009046802A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120277208A1 (en) * 2009-12-11 2012-11-01 Astellas Pharma Inc. Benzamide compound
WO2011095997A1 (en) 2010-02-08 2011-08-11 Advinus Therapeutics Private Limited Benzamide compounds as glucokinase activators and their pharmaceutical application
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AU2011235212B2 (en) 2010-03-31 2014-07-31 The Scripps Research Institute Reprogramming cells
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN102558149A (zh) * 2010-12-29 2012-07-11 中国医学科学院药物研究所 嘧啶衍生物、及其制法和药物组合物与用途
EP2687531B1 (en) 2011-03-18 2016-07-13 ONO Pharmaceutical Co., Ltd. Tetrahydrocarboline derivative
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US11555031B2 (en) 2017-03-20 2023-01-17 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
WO2022031736A1 (en) 2020-08-04 2022-02-10 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
CN116438171A (zh) 2020-09-16 2023-07-14 努拉生物公司 作为sarm1抑制剂的取代的吡啶衍生物
IL310403A (en) 2021-07-28 2024-03-01 Nura Bio Inc Converted pyridine derivatives as SARM1 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
BRPI0407810A (pt) * 2003-02-26 2006-03-01 Banyu Pharma Co Ltd composto, composição farmacêutica, ativador da glicocinase, e, medicamento
EP2048137A1 (en) 2004-02-18 2009-04-15 AstraZeneca AB Benzamide derivatives and their use as glucokinase activating agents.
BRPI0507734A (pt) 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
GB0423044D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
AU2005293343B2 (en) 2004-10-16 2009-03-19 Astrazeneca Ab Process for making phenoxy benzamide compounds
GB0423043D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
WO2007007040A1 (en) 2005-07-09 2007-01-18 Astrazeneca Ab 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
EP2027113A1 (en) 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP1902052B1 (en) 2005-07-09 2012-11-28 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP1915367A1 (en) 2005-08-09 2008-04-30 AstraZeneca AB Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
GB0606876D0 (en) 2006-04-05 2006-05-17 Glaxo Group Ltd Compounds
WO2008118758A1 (en) * 2007-03-23 2008-10-02 Icagen, Inc. Inhibitors of ion channels

Also Published As

Publication number Publication date
HRP20130377T1 (en) 2013-05-31
WO2009046802A1 (en) 2009-04-16
IL204750A0 (en) 2010-11-30
PL2197849T3 (pl) 2013-05-31
EP2197849A1 (en) 2010-06-23
EA017114B1 (ru) 2012-09-28
AU2008310115A1 (en) 2009-04-16
AU2008310115B2 (en) 2013-06-27
KR20100066580A (ko) 2010-06-17
US8236824B2 (en) 2012-08-07
CY1113944T1 (el) 2016-07-27
NZ585237A (en) 2012-03-30
PT2197849E (pt) 2013-04-23
CN101821240A (zh) 2010-09-01
ECSP10010163A (es) 2010-06-29
JP5457358B2 (ja) 2014-04-02
ES2403105T3 (es) 2013-05-14
CA2701839A1 (en) 2009-04-16
JP2010540669A (ja) 2010-12-24
US20100210690A1 (en) 2010-08-19
EP2197849B1 (en) 2013-02-27
SI2197849T1 (sl) 2013-05-31
DK2197849T3 (da) 2013-03-25
AR068749A1 (es) 2009-12-02
UA99837C2 (en) 2012-10-10
BRPI0818348A2 (pt) 2015-04-07
MX2010003760A (es) 2010-04-21

Similar Documents

Publication Publication Date Title
EA201000562A1 (ru) Производные n-(пиразол-3-ил)бензамида в качестве активаторов глюкокиназы
EA201001358A1 (ru) Активаторы глюкокиназы
EA201000561A1 (ru) Производные пиридина, пригодные в качестве активаторов глюкокиназы
EA201001367A1 (ru) Производные карбоксамид-гетероарила для лечения диабета
EA201200653A1 (ru) Гетариламинохинолины
EA201000549A1 (ru) Производные пиперидина и пиперазина
EA201101399A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
EA201200119A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
EA201001174A1 (ru) ПРОИЗВОДНЫЕ β-АМИНОКИСЛОТ ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА
PE20110294A1 (es) Compuestos heterociclicos como inhibidores de enzimas de senal especifica
MX2008012064A (es) Compuestos de amida 1-fenilsulfonil-diaza-heterociclica y sus usos como moduladores de hidroxiesteroide deshidrogenadas.
NO20076658L (no) Heteroarylbenzamidderivater for anvendelse som GLK aktivatorer ved behandling av diabetes
NZ597352A (en) CRYSTALS of 2-{ 4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy} -N-(methylsulfonyl)acetamide
EA201100880A1 (ru) Бензонафтиридиновые соединения в качестве ингибиторов аутотаксина
ATE472542T1 (de) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
EA200901609A1 (ru) Амиды пиразолкарбоновой кислоты, применимые в качестве микробиоцидов
ATE476418T1 (de) Benzamidderivate und assoziierte verwendungen
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
EA200870474A1 (ru) Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1
ATE471311T1 (de) Inhibitoren von11-beta- hydroxysteroiddehydrogenase 1
ATE472531T1 (de) Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
EA200701840A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
MX2009012708A (es) Derivados de piridazinona.
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA201100125A1 (ru) Производные пирролопиридинилпиримидин-2-иламина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU